Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy

Kristina Sonnenschein1,2, Jan Fiedler1, David de Gonzalo-Calvo1,3,4

  • 1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.

Scientific Reports
|January 20, 2021
PubMed

Insights

We identified c-KIT as a novel biomarker for hypertrophic cardiomyopathy (HCM). Serum c-KIT levels were lower in HCM patients, while cardiac tissue showed higher levels, suggesting its role in fibrosis.

Area of Science:

  • Cardiology
  • Biochemistry
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with obstructive (HOCM) and non-obstructive (HNCM) forms.
  • HCM is characterized by cardiomyocyte hypertrophy and cardiac fibrosis, increasing sudden cardiac death risk.
  • Identifying reliable biomarkers for HCM is crucial for diagnosis and understanding disease mechanisms.

Purpose of the Study:

  • To investigate protein biomarkers for differentiating hypertrophic cardiomyopathy (HCM) patients from healthy individuals.
  • To identify proteins associated with cardiometabolic processes in HCM.
  • To explore the potential of c-KIT as a novel biomarker for HCM.

Main Methods:

  • Protein screening using proximity extension assay technology on 92 cardiometabolic proteins.
  • Quantitative measurement of candidate proteins in a cohort of 60 HCM patients and 28 healthy controls.
  • Validation of potential biomarkers, including c-KIT, in serum and cardiac tissue.

Main Results:

  • c-KIT was the only significantly regulated protein differentiating HCM patients from controls.
  • Serum c-KIT levels were significantly lower in HCM patients compared to healthy controls, even after adjustment.
  • Cardiac tissue from HOCM patients showed significantly higher c-KIT levels, correlating with fibrotic myocardium.

Conclusions:

  • c-KIT is a promising novel biomarker for distinguishing HCM patients from the healthy population.
  • Lower serum c-KIT may indicate disease presence, while higher cardiac tissue levels suggest a role in fibrosis.
  • Further research into c-KIT's functional role in HOCM fibrosis is warranted.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
343
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
555
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
149
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
215